|Chemical and physical data|
|Molar mass||342.75 g·mol−1|
|3D model (JSmol)|
LGD-3303 is a drug which acts as a selective androgen receptor modulator (SARM), with good oral bioavailability. It is a selective agonist for the androgen receptor, producing functional selectivity with effective dissociation of anabolic and androgenic effects, acting as a partial agonist for androgenic effects, but a full agonist for anabolic effects. It has been investigated as a possible treatment for osteoporosis, and was shown in animal studies to enhance the effectiveness of a bisphosphonate drug.
- Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, et al. (February 2009). "Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator". The Journal of Pharmacology and Experimental Therapeutics. 328 (2): 663–70. doi:10.1124/jpet.108.146811. PMID 19017848.
- Vajda EG, Hogue A, Griffiths KN, Chang WY, Burnett K, Chen Y, et al. (February 2009). "Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats". Journal of Bone and Mineral Research. 24 (2): 231–40. doi:10.1359/jbmr.081007. PMID 18847323.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|